The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...

Kentucky leads the nation with 21 prescriptions per 1,000 residents, reflecting its 36.5% obesity rate and robust healthcare access.

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly Asia Ventures.